Antares Pharma, Inc. Release: Drug-Exposure Limitations Of Oral Methotrexate At Doses Greater Than Or Equal To 15 Mg May Be Overcome With Subcutaneous Administration

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate (MTX) in adult patients with rheumatoid arthritis (RA).

Help employers find you! Check out all the jobs and post your resume.